

In the claims:

Please amend claims 66-69, 74-76, 78-82, 87-89, and 91-94.

Please add new claims 95-163.

Claims 1–6    **(Canceled)**

7.     **(Previously presented)**     A method for treating or reducing the advancement, severity or effects of neoplasia comprising administering a therapeutically effective amount of at least two compositions, each composition comprising at least one anti-LT- $\beta$ -R antibody and a pharmaceutically acceptable carrier.

8.     **(Previously presented)**     The method according to claim 7, wherein one anti-LT- $\beta$ -R antibody is CBE11.

9.     **(Previously presented)**     The method according to claim 7, comprising at least two anti-LT- $\beta$ -R monoclonal antibodies which are directed against non-overlapping epitopes of LT- $\beta$ -R.

10.    **(Original)**     The method according to claim 9, wherein one anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of BCG6, BHA10, BKA11, CDH10 and CBE11.

11.    **(Original)**     The method according to claim 9, wherein one anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of BCG6 and BHA10, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BKA11, CDH10, and CBE11.

12.    **(Original)**     The method according to claim 9, wherein one anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of BKA11 and CDH10, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, and CBE11.

13. **(Original)** The method according to claim 9, wherein one anti-LT- $\beta$ -R monoclonal antibody is CBE11, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, BKA11, CDH10 and CBE11.
14. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- $\beta$ -R monoclonal antibody is CBE11 and at least one anti-LT- $\beta$ -R monoclonal antibody is BHA10.
15. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- $\beta$ -R monoclonal antibody is CBE11 and at least one anti-LT- $\beta$ -R monoclonal antibody is CDH10.
16. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- $\beta$ -R monoclonal antibody is AGH1 and at least one anti-LT- $\beta$ -R monoclonal antibody is CDH10.
17. **(Previously presented)** The method according to claim 7, further comprising administering IFN- $\gamma$ .

Claims 18-37 **(Canceled)**

38. **(Previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of at least two anti-LT- $\beta$ -R antibodies, and a pharmaceutically acceptable carrier.
39. **(Previously presented)** The pharmaceutical composition according to claim 38, wherein at least one anti-LT- $\beta$ -R antibody is a monoclonal antibody.
40. **(Original)** The pharmaceutical composition according to claim 39, wherein the anti-LT- $\beta$ -R antibody is CBE11.
41. **(Previously presented)** The pharmaceutical composition according to claim 38, wherein at least two anti-LT- $\beta$ -R antibodies are directed against non-overlapping epitopes of LT- $\beta$ -R.

42. **(Original)** The pharmaceutical composition according to claim 41, wherein one anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of BCG6, BHA10, BKA11, CDH10 and CBE11.
43. **(Original)** The pharmaceutical composition according to claim 41, wherein one anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of BCG6 and BHA10, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, CKA11, CDH10 and CBE11
44. **(Original)** The pharmaceutical composition according to claim 41, wherein one anti-LT-B-R monoclonal antibody is selected from the group consisting of BKA11 and CDH10, and another anti-LT-B-R monoclonal antibody is selected from the group consisting of AGH1 and BDA8, BCG6, BHA10 and CBE11.
45. **(Original)** The pharmaceutical composition according to claim 41, wherein the anti-LT- $\beta$ -R monoclonal antibody is CBE11, and another anti-LT- $\beta$ -R monoclonal antibody is selected from the group consisting of AGH1, BDA8, BCG6, BHA10, BKA11, CDH10, and CBE11.
46. **(Previously presented)** The pharmaceutical composition according to claim 41, wherein at least one anti-LT- $\beta$ -R monoclonal antibody is CBE11 and at least one anti-LT-B-R monoclonal antibody is BHA10.
47. **(Previously presented)** The pharmaceutical composition according to claim 41, wherein at least one anti-LT- $\beta$ -R monoclonal antibody is CBE11 and at least one anti-LT- $\beta$ -R monoclonal is CDH10.
48. **(Previously presented)** The pharmaceutical composition according to claim 41, wherein at least one anti-LT- $\beta$ -R monoclonal antibody is AGH1 and at least one anti-LT- $\beta$ -R monoclonal antibody is CDH10.

49. **(Previously presented)** The pharmaceutical composition according to any one of the claims 41-48, further comprising IFN- $\gamma$ .

Claims 50-60 **(Canceled)**

61. **(Previously presented)** The method according to claim 7, wherein at least one anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

62. **(Previously presented)** The method according to claim 7, wherein at least one anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB 11795.

63. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB 11793

64. **(Previously presented)** The method according to claim 9, wherein at least one anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB 11795.

65. **(Previously presented)** The method according to claim 64, further comprising at least one anti-LT- $\beta$ -R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

66. **(Currently amended)** The pharmaceutical composition according to claim 38, wherein at least one ~~the~~ anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

67. **(Currently amended)** The pharmaceutical composition according to claim 38, wherein at least one ~~the~~ anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

68. **(Currently amended)** The pharmaceutical composition according to claim 41 ~~46~~, wherein at least one anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line CBE11.1, ATCC accession number HB11793.

69. **(Currently amended)** The pharmaceutical composition according to claim 41 ~~46~~, wherein at least one anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB11795.

70. **(Previously presented)** The pharmaceutical composition according to claim 69, further comprising at least one anti-LT- $\beta$ -R antibody having the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

71. **(Previously presented)** The method according to claim 7, wherein the anti-LT- $\beta$ -R antibody comprises CDRs from antibody CBE11 produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793).

72. **(Previously presented)** The method according to claim 7, wherein the anti-LT- $\beta$ -R antibody is selected from the group consisting of CBE11 produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793), BKA11 produced by hybridoma BK.A11.AC10 (ATCC Accession No. HB11799), CDH10 produced by hybridoma CD.H10.1 (ATCC Accession No. HB11797), BCG6 produced by hybridoma BC.G6.AF5 (ATCC Accession No. HB11794), BHA10 produced by hybridoma BH.A10 (ATCC Accession No. HB11795), and AGH1 produced by hybridoma AG.H1.5.1 (ATCC Accession No. HB11796).

73. **(Previously presented)** The method according to claim 7, wherein at least one anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.

74. **(Currently amended)** The method according to claim ~~any one of claims 7, 61-65, 71, and 73~~, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.

75. **(Currently amended)** The method according to claim ~~any one of claims 7, 61-65, 71, and 73~~, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

76. **(Currently amended)** The method according to claim ~~any one of claims 7, 61-65, 71, and 73-75~~, further comprising administering an anti-tumor therapy.

77. **(Previously presented)** The method according to claim 76, wherein the anti-tumor therapy is radiation or chemotherapy.

78. **(Currently amended)** The method according to claim ~~any one of claims 7, 61-65, 71, and 73-75~~, further comprising administering an LT- $\beta$ R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.

79. **(Currently amended)** The pharmaceutical composition according to claim ~~any one of claims 38, 39, and 66-70~~, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

80. **(Currently amended)** The pharmaceutical composition according to claim ~~any one of claims 38, 39, and 66-70~~, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.

81. **(Currently amended)** The pharmaceutical composition according to claim ~~any one of claims 38, 39, and 66-70~~, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.

82. **(Currently amended)** A method for treating or reducing the advancement, severity or effects of neoplasia comprising administering an effective amount of a pharmaceutical composition comprising an anti-LT- $\beta$ -R antibody and a pharmaceutically acceptable carrier, wherein the composition is administered in the presence of an exogenous LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, an interferon inducing agent, and an anti-LT- $\beta$ -R antibody.

83. **(Previously presented)** The method according to claim 82, wherein the anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line CB.E11.1, ATCC accession number HB11793.

84. **(Previously presented)** The method according to claim 82, wherein the anti-LT- $\beta$ -R antibody has the same epitope specificity as an antibody produced by cell line BH.A10, ATCC accession number HB 11795.

85. **(Previously presented)** The method according to claim 82, wherein the anti-LT- $\beta$ -R antibody comprises CDRs from antibody CBE11 produced by hybridoma CB.E11.1, ATCC Accession No. HB11793.

86. **(Previously presented)** The method according claim 82, wherein the anti-LT- $\beta$ -R antibody is selected from the group consisting of CBE11 produced by hybridoma CB.E11.1 (ATCC Accession No. HB11793), BKA11 produced by hybridoma BK.A11.AC10 (ATCC Accession No. HB11799), CDH10 produced by hybridoma CD.H10.1 (ATCC Accession No. HB11797), BCG6 produced by hybridoma BC.G6.AF5 (ATCC Accession No. HB11794), BHA10 produced by hybridoma BH.A10 (ATCC Accession No. HB11795), and AGH1 produced by hybridoma AG.H1.5.1 (ATCC Accession No. HB11796).

87. **(Currently amended)** The method according to claim 82 ~~any one of claims 82-86~~, wherein the anti-LT- $\beta$ -R antibody is a F(ab)2.

88. **(Currently amended)** The method according to claim 82 ~~any one of claims 82-86~~, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

89. **(Currently amended)** The method according to claim 82 ~~any one of claims 82-86~~, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
90. **(Canceled)**
91. **(Currently amended)** The method according to claim 82 ~~any one of claims 82-86~~, further comprising administering an anti-tumor therapy.
92. **(Previously presented)** The method according to claim 91, wherein the anti-tumor therapy is radiation or chemotherapy.
93. **(Currently amended)** The method according to claim ~~any one of claims 7, 61-65, 71, 73~~, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.
94. **(Currently amended)** The method according to claim 82 ~~any one of claims 82-86~~, wherein the anti-LT- $\beta$ -R antibody is a multivalent antibody.
95. **(New)** The method according to claim 61, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.
96. **(New)** The method according to claim 62, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.
97. **(New)** The method according to claim 63, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.
98. **(New)** The method according to claim 64, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.
99. **(New)** The method according to claim 65, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.



100. **(New)** The method according to claim 71, wherein at least one anti-LT- $\beta$ -R antibody is a chimeric antibody.

101. **(New)** The method according to claim 61, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

102. **(New)** The method according to claim 62, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

103. **(New)** The method according to claim 63, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

104. **(New)** The method according to claim 64, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

105. **(New)** The method according to claim 65, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

106. **(New)** The method according to claim 71, wherein at least one anti-LT- $\beta$ -R antibody is a humanized antibody.

107. **(New)** The method according to claim 61, further comprising administering an anti-tumor therapy.

108. **(New)** The method according to claim 62, further comprising administering an anti-tumor therapy.

109. **(New)** The method according to claim 63, further comprising administering an anti-tumor therapy.

110. **(New)** The method according to claim 64, further comprising administering an anti-tumor therapy.
111. **(New)** The method according to claim 65, further comprising administering an anti-tumor therapy.
112. **(New)** The method according to claim 71, further comprising administering an anti-tumor therapy.
113. **(New)** The method according claim 61, further comprising administering an LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.
114. **(New)** The method according claim 62, further comprising administering an LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.
115. **(New)** The method according claim 63, further comprising administering an LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.
116. **(New)** The method according claim 64, further comprising administering an LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.
117. **(New)** The method according claim 65, further comprising administering an LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.

118. **(New)** The method according claim 71, further comprising administering an LT- $\beta$ -R activating agent selected from the group consisting of IFN- $\gamma$ , IFN- $\alpha$ , TNF, and interferon inducing agents.

119. **(New)** The pharmaceutical composition according claim 39, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

120. **(New)** The pharmaceutical composition according claim 66, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

121. **(New)** The pharmaceutical composition according claim 67, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

122. **(New)** The pharmaceutical composition according claim 68, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

123. **(New)** The pharmaceutical composition according claim 69, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

124. **(New)** The pharmaceutical composition according claim 70, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.

125. **(New)** The pharmaceutical composition according to claim 39, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.

126. **(New)** The pharmaceutical composition according to claim 66, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.

127. **(New)** The pharmaceutical composition according to claim 67, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.

128. **(New)** The pharmaceutical composition according to claim 68, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
129. **(New)** The pharmaceutical composition according to claim 69, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
130. **(New)** The pharmaceutical composition according to claim 70, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
131. **(New)** The pharmaceutical composition according to claim 39, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.
132. **(New)** The pharmaceutical composition according to claim 66, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.
133. **(New)** The pharmaceutical composition according to claim 67, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.
134. **(New)** The pharmaceutical composition according to claim 68, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.
135. **(New)** The pharmaceutical composition according to claim 69, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.
136. **(New)** The pharmaceutical composition according to claim 70, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.
137. **(New)** The method according to claim 83, wherein the anti-LT- $\beta$ -R antibody is a F(ab)<sub>2</sub>.

138. **(New)** The method according to claim 84, wherein the anti-LT- $\beta$ -R antibody is a F(ab)2.
139. **(New)** The method according to claim 85, wherein the anti-LT- $\beta$ -R antibody is a F(ab)2.
140. **(New)** The method according to claim 86, wherein the anti-LT- $\beta$ -R antibody is a F(ab)2.
141. **(New)** The method according to claim 83, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.
142. **(New)** The method according to claim 84, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.
143. **(New)** The method according to claim 85, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.
144. **(New)** The method according to claim 86, wherein the anti-LT- $\beta$ -R antibody is a chimeric antibody.
145. **(New)** The method according to claims 83, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
146. **(New)** The method according to claims 84, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
147. **(New)** The method according to claims 85, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.
148. **(New)** The method according to claims 86, wherein the anti-LT- $\beta$ -R antibody is a humanized antibody.

149. **(New)** The method according to claim 82, further comprising administering an anti-tumor therapy.
150. **(New)** The method according to claim 83, further comprising administering an anti-tumor therapy.
151. **(New)** The method according to claim 84, further comprising administering an anti-tumor therapy.
152. **(New)** The method according to claim 85, further comprising administering an anti-tumor therapy.
153. **(New)** The method according to claim 86, further comprising administering an anti-tumor therapy.
154. **(New)** The method according to claim 61, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.
155. **(New)** The method according to claim 62, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.
156. **(New)** The method according to claim 63, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.
157. **(New)** The method according to claim 64, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.
158. **(New)** The method according to claim 65, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.
159. **(New)** The method according to claim 71, wherein at least one anti-LT- $\beta$ -R antibody is a multivalent antibody.

160. **(New)** The method according to claim 83, wherein the anti-LT- $\beta$ -R antibody is a multivalent antibody.

161. **(New)** The method according to claim 84, wherein the anti-LT- $\beta$ -R antibody is a multivalent antibody.

162. **(New)** The method according to claim 85, wherein the anti-LT- $\beta$ -R antibody is a multivalent antibody.

163. **(New)** The method according to claim 86, wherein the anti-LT- $\beta$ -R antibody is a multivalent antibody.